Skip to main content
x

Recent articles

M&A analysis: bolt-ons for J&J and Bristol

The biggest oncology buy of the quarter concerned the prostate cancer player Halda.

One Genmab Rybrevant challenge is rendered moot

GEN1286 looks dead, though MCLA-129 continues for now.

ImmunityBio tries again in papillary bladder cancer

And the company says it won’t need to carry out another trial.

Innovent gives another cytokine a shot

Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.

AstraZeneca goes all-in on AbelZeta’s Car

A fresh licensing deal tidies up years of work between the two companies.

Epkinly fails its first confirmatory test

And that could affect the drug's third-line accelerated approval.